Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ahead. Explore more here.
Eli Lilly, others to buy after RFK-inspired drop, Barron’s says
Stocks of anti-obesity drugmakers Eli Lilly , Novo Nordisk , and Amgen have gotten hit as the market frets over what a Robert F. Kennedy Jr.-run Department of Health and Human Ser
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Owning shares of pharmaceutical giant Eli Lilly (NYSE: LLY) has generally been a great idea over the past year. Lilly's diabetes medication Mounjaro and its sibling treatment for chronic weight management Zepbound have evolved into blockbuster drugs in ...
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid. Eli Lilly now ranks as the largest drugmaker in the world based on market cap. Its remarkable rise has been largely due to the success of its type 2 diabetes and obesity drugs Mounjaro ...
Massive Insider Trade At Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Eli Lilly and Co. (NYSE:LLY) has seen better days. The stock is up 26.04% for the last year but has struggled recently, ...
'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s Valuable’
We recently compiled a list of the Jim Cramer on Nvidia Plus Other Stocks. In this article, we are going to take a look at ...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Healthcare Dive6d
Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...